Advertisement

Pfizer earnings fall but top Wall Street 4Q forecasts

By Associated Press  |  February 02, 2016

Pfizer's fourth-quarter profit fell by half due to higher costs for production, administration and restructuring, but new revenue from an acquisition helped the world's second-biggest drugmaker beat Wall Street expectations.

Dealmaking keeps up heady pace

By Melanie Evans  |  January 23, 2016

Last year ended as frenzied as it began for healthcare dealmakers. Globally, merger and acquisition activity reached record volume in 2015, and the value of global healthcare deals increased 66% last year to $723.7 billion, according to Dealogic.

Drugmakers commit to fight against antibiotic resistance

By Steven Ross Johnson  |  January 21, 2016

More than 80 pharmaceutical, diagnostic and biotech firms are calling for increased government investment of new antibiotic drugs to address the growing threat posed by drug-resistant infections coupled with dwindling innovation of new treatments.

Tumultuous market worries healthcare industry

By Melanie Evans  |  January 09, 2016

Healthcare entered 2016 with market turmoil, and not because of China's economy. Investors grew anxious after third-quarter results last year suggested that the Affordable Care Act's boost to hospitals—and related companies such as staffing firms—had begun to wane.

First-of-a-kind drug approvals continued rise in 2015

By Associated Press  |  January 04, 2016

Approvals for first-of-a-kind drugs climbed last year, pushing the annual tally of new U.S. drugs to its highest level in 19 years. The figures reflect a focus on drugs for rare and hard-to-treat diseases, which often come with streamlined reviews, extra patent protections and higher price tags.

Q&A: Pfizer exec discusses drug price controversies, consumer directed healthcare

Q&A: Pfizer exec discusses drug price controversies, consumer directed healthcare

By Modern Healthcare  |  December 12, 2015

Albert Bourla, group president of vaccines, oncology and consumer healthcare businesses at Pfizer, spoke with Modern Healthcare about his company's research and development strategies, how Pfizer is responding to consumer-directed healthcare and the controversy over high drug prices.

Pharma 'could have done a better job' explaining drug costs, Pfizer exec says

Pharma 'could have done a better job' explaining drug costs, Pfizer exec says

By Modern Healthcare  |  December 12, 2015

Albert Bourla, group president of vaccines, oncology and consumer healthcare businesses at Pfizer, discusses his company's research and development strategies, how Pfizer is responding to consumer-directed healthcare and the controversy over high drug prices. He spoke with Modern Healthcare...

Pfizer-Allergan deal could reduce biosimilar cost savings

Pfizer-Allergan deal could reduce biosimilar cost savings

By Steven Ross Johnson  |  December 05, 2015

Pfizer's $160 billion deal to acquire Irish drugmaker Allergan got a lot of attention for the tax advantages Pfizer would enjoy from moving its New Jersey headquarters overseas to Dublin. There wasn't much talk, though, about how much the deal would expand Pfizer's footprint in biosimilars.

Pfizer, Allergan agree to $160 billion merger

Pfizer, Allergan agree to $160 billion merger

By Modern Healthcare  |  November 22, 2015

The boards of Pfizer and Ireland's Allergan on Sunday approved a merger deal worth $160 billion. The deal would create the largest drugmaker by sales.

New tax inversion rules put damper on pending Pfizer-Allergan deal

By Beth Kutscher  |  November 20, 2015

An expected deal between pharmaceutical giants Pfizer and Allergan that's expected to be worth up to $380 a share could become less lucrative under new U.S. Treasury rules designed to diminish the benefits of cross-border transactions.

Advertisement
Modern Healthcare Daily

Award winning coverage of healthcare business and policy news.

The Modern Healthcare app includes a personalized home screen, strong search functionality and immediate downloads from the industry's leading healthcare media brand.